Rhinitis: Epidemiology Overview and Insights

  • ID: 4523563
  • Report
  • 50 pages
  • Pharma Scroll
1 of 4

FEATURED COMPANIES

  • Abdi Ibrahim
  • AstraZeneca
  • Elan
  • Gruppo Angelini
  • Ligand Pharmaceuticals
  • Mitsubishi Pharma
  • MORE
“Rhinitis: Epidemiology Overview and Insights” report delivers an in-depth understanding of the disease and the historical & forecasted epidemiology of Rhinitis disease in terms of diagnosed prevalent and the treated patients in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan market till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Disease Indication Overview:
This section of the report gives the overview of Rhinitis disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of Rhinitis disease. Further details on the profile of Rhinitis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Rhinitis disease.

Epidemiology Forecasts to 2024:
This section of the report provides the overview of Rhinitis diagnosed prevalent and treated patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Why Purchase the Report:
  • Robust Disease Diagnosed prevalent population numbers for companies’ internal use
  • Robust Disease Drug treated population numbers for companies’ internal use
  • Epidemiology numbers forecasted to 2024
  • Epidemiology numbers can be used by companies as inputs to their internal forecast models
  • Multiple Countries coverage
  • Detailed Disease Insights coverage
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abdi Ibrahim
  • AstraZeneca
  • Elan
  • Gruppo Angelini
  • Ligand Pharmaceuticals
  • Mitsubishi Pharma
  • MORE
Table of Contents:
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Key Metrics

3 Disease Overview
3.1 Disease Definition
3.2 Disease Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Impact on Quality of Life
3.3 Symptoms of the Disease
3.4 Disease Diagnosis
3.5 Treatment Guidelines
3.6 Key unmet needs

4 Disease Epidemiology
4.1 Diagnosed Prevalent Patient projections by Country (Forecast till 2024)
4.1.1 France
4.1.2 Germany
4.1.3 Italy
4.1.4 Spain
4.1.5 United Kingdom
4.1.6 United States
4.1.7 Japan
4.2 Treated Patient projections by Country (Forecast till 2024)
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 United Kingdom
4.2.6 United States
4.2.7 Japan

5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Coverage
5.4 Methodology and Research conducted
5.5 About Us
5.6 Contact Us
5.7 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol-Myers Squibb
  • Ligand Pharmaceuticals
  • Lundbeck
  • Otsuka Holdings
  • Abdi Ibrahim
  • Genovate Biotechnology
  • Eli Lilly
  • Elan
  • Johnson & Johnson
  • Alkermes
  • Merck & Co
  • Daiichi Sankyo
  • Takeda
  • Sumitomo Dainippon Pharma
  • Les Laboratoires Servier
  • Bukwang Pharmaceutical
  • Gruppo Angelini
  • Standard Chem. & Pharm.
  • NewBridge Pharmaceuticals
  • Forest Laboratories
  • Recordati
  • Mitsubishi Tanabe Pharma
  • Gedeon Richter
  • Allergan
  • Schering-Plough
  • Pfizer
  • Meiji Holdings
  • AstraZeneca
  • Mitsubishi Pharma
  • Cyrenaic Pharmaceuticals
  • Minerva Neurosciences
  • Intra-Cellular Therapies
  • ACADIA Pharmaceuticals
  • Ipsen
  • Astellas Pharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll